Dogwood Therapeutics (NASDAQ:DWTX) Issues Earnings Results

Dogwood Therapeutics (NASDAQ:DWTX) issued its earnings results on Wednesday. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.22) by $0.96, FiscalAI reports.

Dogwood Therapeutics Trading Down 8.8%

NASDAQ:DWTX opened at $2.71 on Friday. Dogwood Therapeutics has a 1 year low of $2.60 and a 1 year high of $9.50. The stock has a 50-day moving average price of $2.95 and a two-hundred day moving average price of $4.68. The stock has a market cap of $86.94 million, a price-to-earnings ratio of -0.14 and a beta of 1.90.

Analyst Ratings Changes

DWTX has been the topic of a number of analyst reports. Wall Street Zen downgraded shares of Dogwood Therapeutics to a “strong sell” rating in a research report on Saturday, December 13th. HC Wainwright restated a “buy” rating and set a $12.00 price objective on shares of Dogwood Therapeutics in a report on Friday, February 20th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Dogwood Therapeutics in a research note on Monday, December 22nd. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $12.00.

Hedge Funds Weigh In On Dogwood Therapeutics

A hedge fund recently bought a new stake in Dogwood Therapeutics stock. Marshall Wace LLP acquired a new stake in Dogwood Therapeutics, Inc (NASDAQ:DWTX) in the 4th quarter, according to its most recent filing with the SEC. The fund acquired 11,655 shares of the company’s stock, valued at approximately $48,000. Marshall Wace LLP owned 0.51% of Dogwood Therapeutics as of its most recent filing with the SEC. Institutional investors and hedge funds own 9.05% of the company’s stock.

Dogwood Therapeutics Company Profile

Dogwood Therapeutics is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.

Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.